Up­dat­ed: FDA adds warn­ing of 'larg­er ar­eas of bleed­ing' in brain to Bio­gen's Aduhelm la­bel

The FDA last week signed off on a safe­ty-re­lat­ed change to the la­bel of Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm, which has bare­ly mus­tered any sales …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.